Clinical Trials Arena on MSN
Celea Therapeutics engages regulators ahead of Phase III deupirfenidone IPF trial
Established by PureTech to advance deupirfenidone, Celea Therapeutics believes that this data, delivered in a late-breaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback